UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 425

Sortiert nach

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

Science translational medicine, 2015-04, Vol.7 (283), p.283ra51

2015

Volltextzugriff (PDF)

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

JNCI : Journal of the National Cancer Institute, 2020-01, Vol.112 (1), p.46-54

2020

Volltextzugriff (PDF)

Correction: Differential response to donepezil in MRI subtypes of mild cognitive impairment

Alzheimer's research & therapy, 2023-10, Vol.15 (1), p.177-177, Article 177

2023

Volltextzugriff (PDF)

Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies

Alzheimer's & dementia, 2024-04, Vol.20 (4), p.2485-2496

2024

Volltextzugriff (PDF)

Controlled release of 1-methylcyclopropene from its functionalised electrospun fibres under constant and linearly ramped humidity

Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment, 2017-10, Vol.34 (10), p.1690-1702

2017

Volltextzugriff (PDF)

Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control

Journal of Virology, 2006-03, Vol.80 (6), p.3122-3125

2006

Volltextzugriff (PDF)

Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis

Frontiers in pharmacology, 2020-11, Vol.11, p.569373

2020

Volltextzugriff (PDF)

Clinical implications of the intrinsic molecular subtypes of breast cancer

Breast (Edinburgh), 2015-11, Vol.24, p.S26-S35

2015

Volltextzugriff (PDF)

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Breast cancer research : BCR, 2020-05, Vol.22 (1), p.45-45, Article 45

2020

Volltextzugriff (PDF)

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13), p.3540-3550

2017

Volltextzugriff (PDF)

Cerebrovascular Disease and Depressive Symptomatology in Individuals With Subjective Cognitive Decline: A Community-Based Study

Frontiers in aging neuroscience, 2021-07, Vol.13, p.656990-656990

2021

Volltextzugriff (PDF)

Differential response to donepezil in MRI subtypes of mild cognitive impairment

Alzheimer's research & therapy, 2023-06, Vol.15 (1), p.117-117, Article 117

2023

Volltextzugriff (PDF)

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

Cancer treatment reviews, 2020-03, Vol.84, p.101965-101965, Article 101965

2020

Volltextzugriff (PDF)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Nature communications, 2020-01, Vol.11 (1), p.385-385, Article 385

2020

Volltextzugriff (PDF)

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

Clinical cancer research, 2020-11, Vol.26 (22), p.5820-5829

2020

Volltextzugriff (PDF)

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

Nature communications, 2023-03, Vol.14 (1), p.1157-1157, Article 1157

2023

Volltextzugriff (PDF)

The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment

Cell reports (Cambridge), 2014-03, Vol.6 (6), p.1059-1072

2014

Volltextzugriff (PDF)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

Breast cancer research : BCR, 2019-09, Vol.21 (1), p.108-108, Article 108

2019

Volltextzugriff (PDF)

CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial

The oncologist (Dayton, Ohio), 2024-05, Vol.29 (5), p.e622-e634

2024

Volltextzugriff (PDF)

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response

Nature communications, 2024-07, Vol.15 (1), p.5826-13, Article 5826

2024

Volltextzugriff (PDF)

1 – 25 von 425

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(370)
Mit Volltextzugriff
(397)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(22)
Salud Pública De México
(22)
Alzheimer's & Dementia
(16)
Adicciones
(12)
Plos One
(12)
Journal Of Clinical Oncology
(10)
Clinical Cancer Research
(7)
Angewandte Chemie
(6)
Revista Panamericana De Salud Pública
(6)
Frontiers In Oncology
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

Correction: Differential response to donepezil in MRI subtypes of mild cognitive impairment

Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies

Controlled release of 1-methylcyclopropene from its functionalised electrospun fibres under constant and linearly ramped humidity

Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control

Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis

Clinical implications of the intrinsic molecular subtypes of breast cancer

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

Cerebrovascular Disease and Depressive Symptomatology in Individuals With Subjective Cognitive Decline: A Community-Based Study

Differential response to donepezil in MRI subtypes of mild cognitive impairment

Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response

Suchergebnisse filtern